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ABSTRACT
RET, BRAF and other protein kinases have been identified as major molecular 
players in thyroid cancer. To identify novel kinases required for the viability of thyroid 
carcinoma cells, we performed a RNA interference screening in the RET/PTC1(CCDC6-
RET)-positive papillary thyroid cancer cell line TPC1 using a library of synthetic small 
interfering RNAs (siRNAs) targeting the human kinome and related proteins. We 
identified 14 hits whose silencing was able to significantly reduce the viability and 
the proliferation of TPC1 cells; most of them were active also in BRAF-mutant BCPAP 
(papillary thyroid cancer) and 8505C (anaplastic thyroid cancer) and in RAS-mutant 
CAL62 (anaplastic thyroid cancer) cells. These included members of EPH receptor 
tyrosine kinase family as well as SRC and MAPK (mitogen activated protein kinases) 
families. Importantly, silencing of the identified hits did not affect significantly the 
viability of Nthy-ori 3-1 (hereafter referred to as NTHY) cells derived from normal 
thyroid tissue, suggesting cancer cell specificity. The identified proteins are worth 
exploring as potential novel druggable thyroid cancer targets.
INTRODUCTION
Thyroid cancer is the most common endocrine 
malignancy, whose incidence has been steadily increasing 
over the past 30 years [1–3]. Most common thyroid cancer 
types arise from follicular epithelial cells and are classified 
in well-differentiated papillary (PTC) and follicular 
(FTC), poorly differentiated (PDC), and anaplastic 
(undifferentiated) (ATC) carcinoma; PTC accounts for the 
vast majority of thyroid cancer cases [1–3].
Oncogenic conversion of kinases involved in the 
MAPK (mitogen activated protein kinases) and PI3K 
(phosphatidyl-inositol-3-kinase)/AKT signaling cascades 
occurs in thyroid cancer [1–4]. Accordingly, point 
mutations of the BRAF serine/threonine kinase as well 
as rearrangements (RET/PTC) of RET receptor tyrosine 
kinase (RTK) or of other RTKs are found in the majority 
of PTC cases [1–6]. Mutations of RAS, an upstream 
activator of both MAPK and PI3K, are common in FTC 
and in follicular-variant PTC [5–7]. Mutations or copy 
number alterations of PI3K and AKT are found in ATC 
and radioiodine-refractory thyroid cancer [3, 8–10].
Unbiased RNA interference (RNAi) screenings, 
based on the use of siRNAs collections targeting the entire 
genome or relevant gene families, are being exploited to 
identify novel molecular mediators of tumorigenesis and 
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therapeutic targets [11]. Here, through a siRNA-based 
kinome screen, we identified a set of kinases and related 
proteins as novel drivers of thyroid cancer cells viability.
RESULTS
High-throughput siRNA-based screening in 
TPC1 thyroid cancer cells
We designed a functional screening using the 
human papillary carcinoma cell line, TPC1, harboring 
at the endogenous level the RET/PTC1 (CCDC6-RET) 
rearrangement [12] and a commercially available siRNA 
library containing synthetic siRNAs targeting the 518 
human protein kinases as well as kinase-related and 
-associated proteins. The library included two independent 
siRNAs targeting each transcript and negative controls 
consisting of siRNAs targeting green fluorescent protein 
(GFP), eight non targeting scrambled sequences, as well 
as buffer alone. The screening was performed in duplicate. 
Seventy-two hours after transfection, viable cells were 
stained and antiproliferative hits were identified as genes 
whose knock-down, by at least one of the two siRNAs, 
reduced (by at least 30%; loess-log ≤-0.5) cell viability 
in both replicates upon normalization to the median value 
of negative controls. A plot of the results is shown in 
Supplemental Information, Figure S1 and raw data are 
available in Supplemental Information, Table S1. Overall, 
silencing of 50 genes reduced TPC1 cell viability. This 
list included a pseudogene LOC392265 and a Ser/Thr-like 
kinase MGC44796 (later identified as STK40) that were 
excluded from further studies (Supplemental Information, 
Table S2).
Though TPC1 cells depend on RET/PTC1 for their 
viability [12], RET was not present among the hits because 
the two RET targeting siRNAs included in our library did 
not efficiently knock-down the RET/PTC1 expression 
(data not shown).
Validation of antiproliferative hits in TPC1 cells
To confirm the results of the screening, we measured 
TPC1 cell viability upon transfection with the same 2 
siRNAs from the library (siRNA1 and 2) as well as with 2 
independent siRNAs (siRNA3 and 4) targeting a distinct 
mRNA region of the 48 hits (Supplemental Information, 
Table S2); average results are reported in Figure 1 and 
raw data are shown in Supplemental Information, Table 
S3. Nine out of 48 genes were not confirmed to reduce cell 
viability and were therefore excluded from further tests. 
Among the remaining ones, silencing of 27 genes reduced 
dye incorporation by at least 30% (loess-log ≤-0.5) 
Figure 1: Identification of genes essential for TPC1 cell viability. TPC1 cells were transfected in duplicate with 4 independent 
siRNAs (Supplemental Information, Table S2) targeting different regions of the 48 antiproliferative hits. Seventy-two hours after transfection, 
cell viability was measured by CellTiter-Blue assay and expressed as log2 (loess-log normalization). The reported values are the average 
results of the transfection of 4 siRNAs for each gene in duplicate normalized by negative controls (average results of Non specific siRNA 
Control and AllStars Negative siRNA Control). The bars represent 95% confidence intervals. Dotted line represents an arbitrary cut-off 
value (loess-log ≤-0.5) applied to select the down hits.
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(average value of the 4 different siRNAs) as compared 
to the negative controls (siRNAs with no homology 
to any known mammalian gene: Non specific siRNA 
Control, catalogue no. 1022079 and AllStars Negative 
siRNA Control, catalogue no. SI03650318, Qiagen); 
in particular, in the case of 20 genes the reduction was 
significant (p <0.05) with each one of the four different 
used siRNAs. We therefore restricted our analysis to these 
20 hits and tested effects of their silencing in a control 
cell line (NTHY) obtained from normal thyroid tissue and 
immortalized by SV40 Large T. Silencing of six (CIB3, 
ITPKA, MAPK7, MARCKS, PAK2, STK33) genes 
affected the viability also of control cells (data not shown) 
and therefore they were excluded from further tests, thus 
finally resulting in 14 selected hits (Table 1 and Figure 2).
Validation of antiproliferative hits in a panel of 
thyroid cancer cell lines
We sought to test whether effects of the 14 
antiproliferative hits were restricted to TPC1 or common 
to other thyroid cancer cell lines driven by oncogenes 
different from RET. To this aim, we selected 3 additional 
thyroid cancer cell lines (BCPAP, 8505C and CAL62) of 
different histotypes and featuring different complements 
of genetic lesions. BCPAP and 8505C cells bear a BRAF 
V600E and CAL62 bears a KRAS G12R mutation, 
respectively (Supplemental Information, Table S4) [13]. 
The 14 hits were individually silenced by siRNA1 and 2 
in the three cancer cell lines, compared to NTHY cells. 
Silencing of most of them (14/14 genes for BCPAP, 
11/14 for CAL62 and 14/14 for 8505C cells) significantly 
(p <0.01) reduced viability of cancer (Figure 3) but not 
NTHY (Figure 4) cells. Exceptions were represented by 
FYN and PRKACB that reduced CAL62 cell viability 
only when silenced with siRNA1 and LIMK1 that did not 
reduce dye incorporation with either siRNA.
To confirm gene knock-down, we performed 
quantitative RT-PCRs in TPC1 and NTHY cells transiently 
transfected with siRNA1 and siRNA2 for the 14 selected 
hits (Supplemental Information, Table S5). In all the cases, 
mRNA targets were significantly (p <0.05) depleted by 
cognate siRNAs with respect to negative control (AllStars 
Negative Control siRNA) (Figure 5).
Table 1: List of the 14 antiproliferative hits identified in TPC1 cells
Symbol Gene name Genbank ID
AGC: cAMP-dependent, cGMP-dependent and protein kinase C
AKT2 v-akt murine thymoma viral oncogene homolog 2 NM_001626
PKN1 protein kinase N1 NM_002741
PRKACB protein kinase cAMP dependent, catalitic, beta NM_182948
CMGC group
AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 NM_005751
MAP3K7IP1 mitogen-activated protein kinase kinase kinase 7 interacting protein 1 NM_006116
GPCR coupled kinases
GRK4 G protein-coupled receptor kinase 4 NM_182982
STE: serine/threonine kinase family
MAPKAPK2 mitogen-activated protein kinase-activated protein kinase 2 NM_004759
TK: tyrosine kinases
EPHA2 EPH receptor A2 NM_004431
EPHA7 EPH receptor A7 NM_004440
EPHB2 EPH receptor B2 NM_017449
EPHB6 EPH receptor B6 NM_004445
FYN FYN oncogene NM_002037
HCK hemopoietic cell kinase NM_002110
TKL: tyrosine kinase like
LIMK1 LIM domain kinase 1 NM_002314
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Antiproliferative effect of the 14 hits in thyroid 
cancer cells
To better characterize the biological effect of the 
knock-down of the 14 hits, we performed cell count and 
DNA synthesis measurement (BrdU assay). Transfection 
of siRNA1 and 2 against all of the 14 hits significantly (p 
<0.05) decreased cell number (Figure 6, upper) and BrdU 
incorporation (Figure 7, upper) in TPC1 but not in NTHY 
cells (Figure 6-7, lower).
Finally, we asked whether differential expression 
levels can account for the differential effect observed in 
cancer with respect to control NTHY cells. Only minor 
differences in the expression levels of the 14 genes 
were observed when tested by semiquantitative RT-PCR 
in the panel of cell lines used for this study, with the 
Figure 2: Effects on cell viability of different siRNAs in TPC1 cells. TPC1 cellswere transfected in triplicate with 4 independent 
siRNAs (listed in Supplemental Information, Table S2) targeting different regions of the 14 antiproliferative hits. Seventy-two hours after 
transfection, cell viability was measured by CellTiter-Blue assay and expressed as log2 (loess-log normalization). The reported values are 
the average results of the transfection of 4 siRNAs for each gene in triplicate normalized by the scrambled control (average value of Non 
specific siRNA Control and AllStars Negative siRNA Control). The bars represent 95% confidence intervals. Significance was calculated 
by a paired, two-tailed Student’s t test; **: p ≤0.01.
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exception of EPHA7, EPHB2 and EPHB6 that resulted 
highly expressed in some cancer cell lines compared to 
NTHY cells (Figure 8). Moreover, even genes with a low 
expression level had robust effects on cell viability and 
proliferation (Figure 8).
DISCUSSION
Here, we applied a RNAi-based loss-of-function 
screen to identify protein kinases (and kinase-related 
proteins) required for viability of thyroid cancer 
cells. We focused on protein kinases because of their 
frequent involvement in thyroid cancer [1–6] and 
their “druggability” [13, 14]. We identified a set of 14 
antiproliferative hits that, when silenced, impaired the 
viability of various thyroid cancer cell lines. Importantly, 
though the screening was initially conducted on a RET/
PTC1-positive cell line (TPC1), subsequent validation 
experiments proved that sensitivity to knock-down of the 
14 genes was shared by most thyroid cancer cell lines 
harboring different oncogenic lesions (BRAF mutation 
in BCPAP and 8505C and KRAS mutation in CAL62). 
This is noteworthy because BRAF mutation is recognized 
as risk factor for thyroid cancer progression [1, 3] and 
because, so far, KRAS proteins have proved very difficult 
to be directly targeted [15]. P53 mutation is a marker of 
aggressive thyroid cancers [1, 3] and effects of siRNA-
mediated kinase knock-down were not dependent on 
functional P53 because some of the used cell lines were 
P53-mutated (Supplemental Information, Table S4). 
Finally, immortalized thyrocytes coming from non tumoral 
tissue were not sensitive to knock-down of the 14 hits; 
a fact that warrants a therapeutic window for approaches 
aimed at inhibiting these hits in thyroid cancer.
Overall, the 14 hits list included 3 cytosolic 
tyrosine kinases, 4 receptor tyrosine kinases (all 
belonging to the EPH family), and 7 serine/threonine 
kinases. This list was enriched for: i) EPH receptors 
(EPHA2, EPHA7, EPHB2, EPHB6); ii) SRC family 
kinases (FYN, HCK); iii) kinases belonging to the p38 or 
JNK signaling cascades (MAP3K7IP1, MAPKAPK2 and 
PKN1); iv) proteins of PI3K/mTOR signaling (AKT2) 
or the PKA/cyclic AMP pathway (PRKACB, AKAP9) 
(Table 1). Some of these proteins were previously 
involved in thyroid cancer, such as: AKAP9, that was 
rearranged with BRAF in radiation-associated PTC [16], 
Figure 3: Effects on cell viability of silencing of the 14 antiproliferative hits in independent thyroid cancer cell lines. 
BCPAP, CAL62, and 8505C cellswere transfected in triplicate with 2 siRNAs (siRNA1 and siRNA2) targeting different regions of the 
14 antiproliferative hits. Seventy-two hours after transfection, cell viability was measured by CellTiter-Blue assay and expressed as log2 
(loess-log normalization). The reported values are the average results of the transfection of 2 siRNAs for each gene in triplicate normalized 
by the scrambled control (AllStars Negative siRNA Control). The bars represent 95% confidence intervals. Significance was calculated by 
a paired, two-tailed Student’s t test; *: p ≤0.05; **: p ≤0.01.
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GRK4, that was overexpressed in thyroid nodules [17], 
EPHA2, that was overexpressed in thyroid cancer [18, 
19], LIMK1 that is targeted by an onco-miR (miR-20a) 
in thyroid cancer cells [20] and AKT2 that was found 
upregulated in thyroid cancer and involved in transgenic 
mouse models of thyroid cancer [21–24]. Thus, most 
of the identified hits are involved in pathways linked to 
thyroid cancer: SRC family kinases have been previously 
involved in RET/PTC signal transduction [25] and in 
thyroid cancer cell viability [26], JNK and p38MAPK 
have been found to be activated by RET oncogenes 
[27, 28] and p38MAPK targeting has been described 
to effectively reduce proliferation of TPC1 cells [29]. 
Finally, a screening from radiation related PTCs 
Figure 4: Effects on cell viability of silencing of the 14 antiproliferative hits in NTHY cells. NTHY cellswere transfected in 
triplicate with 2 independent siRNAs (siRNA1 and siRNA2) targeting different regions of the 14 antiproliferative hits. Seventy-two hours 
after transfection, cell viability was measured by CellTiter-Blue assay and expressed as log2 (loess-log normalization). The reported values 
are the average results of the transfection of 2 siRNAs for each gene in triplicate normalized by the scrambled control (AllStars Negative 
siRNA Control). The bars represent 95% confidence intervals. Significance was calculated by a paired, two-tailed Student’s t test.
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identified, among other genes, also the upregulation 
of PRKAA1, PDLIM1 and MAPKAPK3 that are 
close relatives of PRKACB, LIMK1 and MAPKAPK2 
identified in our screening [30].
Among the antiproliferative hits, the largest group 
(4/14) was represented by tyrosine kinase receptors of the 
EPH family. EPH receptors are divided in two families: 
EPHAs that preferentially bind to GPI-linked ephrin A 
(EFN-A) ligands, and EPHB that bind transmembrane 
ephrin B (EFN-B) ligands. EPH-EFN complexes 
emanate bidirectional signaling: forward signals that 
depend on EPH tyrosine-kinase activity, and reverse 
signals depending on SRC family kinases associated to 
the cytosolic side of EFN [31]. EPHs signaling controls 
many functions including cell migration, invasion, 
proliferation and survival. These activities in cancer 
are complex and dichotomic, pro-tumorigenic in some 
instances and anti-oncogenic in others [31]. For instance, 
Figure 5: Effects on mRNA levels exerted by silencing of the 14 selected antiproliferative hits. TPC1 A. and NTHY B. 
were transiently transfected with siRNA1 and siRNA2. After 72 hours, mRNA levels of the siRNA targets were measured by quantitative 
RT-PCR. Fold changes for each target (dark bars) were calculated with the formula: 2-(gene of interest ΔCt - control ΔCt), where ΔCt is the difference 
between the amplification fluorescent threshold of the mRNA of interest and the mRNA of ß-actin used as an internal reference. Control 
(white bars) was represented by scrambled siRNA (AllStars Negative siRNA Control) and was arbitrarily set at 1.0. Average results of three 
independent PCR reactions with upper 95% confidence intervals are reported. Significance was calculated by a paired, two-tailed Student’s 
t test; *: p ≤0.05; **p ≤0.01.
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EPHA2 overexpression causes oncogenic transformation 
of mammary epithelial cells [32, 33], was found essential 
for tumour growth [34, 35] and able to mediate resistance 
to BRAF kinase inhibitors in melanoma [36]. Noteworthy, 
EPHA4 is expressed in follicular cell progenitors and it 
is important for normal thyroid development since its 
ablation caused histological alterations of developing 
thyroid gland [37]. Moreover, functional interactions 
between RET, EPHA4 and EFN in motor neurons have 
been reported [38, 39]. In addition, enhanced EphB6 
expression has been detected to be more frequently 
observed in malignant compared to benign thyroid lesions 
[40]. Enhanced EphB6 expression was significantly 
associated with larger tumor size, the presence of lymph 
node metastases, the presence of capsular, lymphatic and 
vascular invasion and increased risk of recurrence. In a 
similar way, EPHA7 has been involved in tumor growth 
and progression of medulloblastoma and glioblastoma 
multiforme (GBM) [41, 42] as well as in NSCLC [43]. 
Depletion of EphA7 has remarkably inhibited the 
Figure 6: Reduction of cell number by silencing of the 14 antiproliferative hits. TPC1 A. and NTHY B. were transfected in 
triplicate with siRNA1 and 2. Seventy-two hours after transfection, cells were counted. Average cell counts upon the transfection of the 2 
siRNAs in triplicate are reported (dark bars). Control was represented by scrambled siRNA (AllStars Negative siRNA Control) (white bars). 
Upper 95% confidence intervals are shown. Significance was calculated by a paired, two-tailed Student’s t test; *: p ≤0.05; **: p ≤0.01.
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Figure 7: Inhibition of DNA synthesis by silencing of the 14 antiproliferative hits. TPC1 A. and NTHY B. cells were 
transfected in triplicate with 2 independent siRNAs (siRNA1 and 2, Supplemental Information, Table S2) targeting the 14 antiproliferative 
hits. Seventy-two hours after transfection, cell were pulsed with BrdU for 2 hours, fixed and BrdU incorporation was detected by a 
peroxidase-conjugated anti-BrdU antibody. Results were read by a microplate reader and calculated as % reduction with respect to the 
negative control represented by scrambled siRNA (AllStars Negative siRNA Control). Average results of the transfection of individual 
siRNA in triplicate for each gene are reported. The bars represent 95% confidence intervals. Significance was calculated by a paired, two-
tailed Student’s t test; **: p ≤0.01.
Figure 8: Expression level of the 14 identified hits in a panel of normal and thyroid cancer cell lines. The level of 
expression of the 14 antiproliferative hits was tested by semiquantitative RT-PCR in normal (NTHY) and cancer (TPC1, BCPAP, 8505C 
and CAL62) thyroid cell lines. GAPDH is shown for normalization.
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proliferation and invasion in human laryngeal cancer 
cell lines [44]. On the other hand, EPHA7 has been 
identified as a soluble tumor suppressor for follicular 
lymphoma [45]. Finally, overexpression of EPHB2 has 
been detected in human cholangiocarcinoma (CCA), 
cutaneous squamous cell carcinoma (cSCC) and cervical 
cancer where it regulates an EMT program through R-Ras 
activation [46–48] while EPHB2 cytosolic localization 
has been shown to predict poor survival in breast cancer 
patients [49]. Interestingly, EPHB2 has been shown 
to have a pro-invasive role also in other tumor models, 
such as in GBM, where on the other side it shows anti-
proliferative actions, suggesting a dichotomic role. A 
tumor suppressor role for EPHB2 through induction of 
autophagic cell death via concomitant activation of the 
ERK1/2 and PI3K pathways has also been described [50].
Oncogenic kinase targeting, either with monoclonal 
antibodies or small molecule kinase inhibitors, has 
emerged as a promising strategy for different human 
cancer types [14]. Thyroid cancer patients are treated 
by thyroidectomy and ablation of residual tissue with 
radioactive iodine. However, thyroid cancers may 
concentrate iodine poorly as the disease becomes less 
differentiated, thus limiting radioiodine efficacy [51, 52]. 
Antiproliferative hits identified through this screen may be 




We used thyroid cancercells featuring different 
genetic lesions (Supplemental Information, Table S4). 
TPC1 and BCPAP cell lines were derived from papillary 
thyroid cancer (PTC), while CAL62 and 8505C were 
derived from anaplastic thyroid cancer (ATC) [53]. Cells 
were authenticated by SNP genotyping (BMR Genomics, 
Padova, Italy) and were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% Foetal 
Bovine Serum (FBS) (Invitrogen, Carlsbad, CA, USA), 
L-glutamine and penicillin/streptomycin (Sigma Aldrich, 
St Louis, MO, USA). Nthy-ori 3-1 (hereafter referred to 
as NTHY) (ECACC, Wiltshire, UK) is a human follicular 
epithelial cell line derived from a normal thyroid and has 
been immortalized by SV40 large T gene [54]. NTHY 
cells were grown in RPMI-1640 medium supplemented 
with 10% FBS (Invitrogen). All cells were expanded in 
culture and cryopreserved in multiple replicate vials.
Primary siRNA screening
Initially, siRNA transfection conditions were set 
up for TPC1 cells by using the KDalert GAPDH kit 
(Ambion, Applied Biosystem, Carlsbad, CA, USA) that 
measures the silencing efficiency of GAPDH, used as a 
reference control. Then, for the screening, TPC1 cells 
were transfected with the human kinome siRNA set v2.0 
(Qiagen, Germantown, MD, USA) in black, transparent 
bottom, 384/well plates (BD Biosciences, Heidelberg, 
Germany). Each well contained a specific siRNA targeting 
one of 709 distinct genes coding for kinases and kinase-
related or -associated proteins. Two siRNAs for each 
target were used. Negative controls were represented by 
8 different scrambled siRNAs, green–fluorescent protein 
(GFP) siRNA, and buffer alone. Four μl of a 0.165 
micromolar siRNA solution were transferred from the 
stock plates. 10 μl of Optimem medium (Invitrogen) was 
mixed with 0.2 μl of HiPerfect cell transfection reagent 
(Qiagen) and after 10 minutes incubation, the transfection 
mix was transferred to each well using an automatic 
MultiDrop dispenser (Thermo Labsystems, Philadelphia, 
PA, USA). The cells were plated at 1,000 cells/well in a 
volume of 35 μl of DMEM supplemented with 2.5% FBS 
without antibiotics. Seventy-two hours after transfection, 
CellTiter-Blue reagent (CellTiter- Blue®, Promega, 
Madison, WI, USA) (10 μl) diluted (1:1) in culture 
medium was added to each well. Plates were incubated 
at 37 °C, in 5% CO2 for 6 hours and then transferred to 
room temperature for overnight incubation, at dark. Cell 
viability was measured by dye reduction with an EnVision 
Multilabel plate reader at an excitation wavelength of 530 
nm and emission wavelength of 590 nm (Perkin Elmer, 
Waltham, MA, USA). The raw data were smoothed using 
loess-correction and subsequently normalized to the 
median of the negative controls and log2-transformed 
(loess-log normalization). siRNAs reducing cell viability 
by ≥2SD (Standard Deviations) of the median of the 
controls were considered as antiproliferative hits. The 
screening was performed in duplicate and the hits 
replicated in both of the screens (loess log ≤-0.53 and 
≤-0.88, respectively) were selected for further validation.
Validation screening
An independent set of 2 siRNAs (Qiagen) for each 
of the 48 identified antiproliferative hits was obtained. The 
list of the 4 siRNAs (those of the library, siRNA 1-2, and 
the additional ones, siRNA 3-4) for each antiproliferative 
hit is provided in Supplemental Information, Table S2. 
TPC1 cells were transfected in duplicate in multi-wells 
with the 4 siRNAs for each antiproliferative hit. Negative 
control was represented by scrambled siRNAs with no 
homology to any known mammalian gene (Non specific 
siRNA Control, catalogue no. 1022079 and AllStars 
Negative siRNA Control, catalogue no. SI03650318, 
Qiagen). Cell viability data were obtained and normalized 
as in the primary screening. siRNAs effective at reducing 
cell viability by at least 30% (loess-log ≤-0.5) were 
selected for further studies.
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Quantitative RT-PCR
Each cell line was grown to 70% confluence, total 
RNA was extracted with RNeasy mini kit (Qiagen) and 
subjected to on-column DNase digestion with the RNase-
free DNase set (Qiagen) according to the manufacturer’s 
instructions. RNA (1μg) was reverse transcribed (RT) 
using a high-capacity reverse transcriptase kit (Quantitect 
Reverse® Transcription Kit, Qiagen). Primers were 
designed by using software available http://bioinfo.ut.ee/
primer3/ and synthesized by the Ceinge Core Service 
Unit (Naples, Italy). The list of primers is provided 
in Supplemental Information, Table S5. ThecDNA 
amplification was performed using the GeneAmp RNA 
PCR Core Kit system (Qiagen) using 2.5 μl of RT product 
in a reaction volume of 25 μl with cycles of 42 °C for 
15 minutes, 99 °C for 5 minutes, and 5 °C for 5 minutes 
according to the manufacturer’s instructions. Quantitative 
RT-PCR reactions were performed in triplicate by using the 
SYBR Green PCR Master mix (Applied Biosystems) and 
the iCycler apparatus (Bio-Rad Laboratories, Berkeley, 
CA, USA). Fluorescent threshold values were measured 
in triplicate and fold changes were calculated by the 
formula: 2-(sample 1 ΔCt - sample 2 ΔCt), where ΔCt is the difference 
between the amplification fluorescent threshold (Ct) of the 
mRNA of interest and the Ct of the ß actin mRNA used as 
housekeeping gene: 5'-TGCGTGACATTAAGGAGA-3' 
(forward) and 5'-GCTCGTAGCTCTTCTCCA-3' 
(reverse). Semiquantitative RT-PCR analysis was carried 
out with cDNAs generated from 1μg of total RNA. The 
RT-PCR exponential phase was determined on 25-30 
cycles to allow semiquantitative comparison of different 
cDNAs using JumpStart REDTaq Reaction Mix, (Sigma). 
GAPDH mRNA was used as housekeeping gene: 
5'-CCATCACCATCTTCCAGGAGCG-3' (forward) and 
5'-AGAGATGATGACCCTTTTGGC-3' (reverse).
Proliferation assays
Cell count was performed by plating 100,000 cells 
in 6 cm dishes and counting the cell number 72 hours after 
siRNA transfection. DNA replication rate was evaluated 
by 5'-bromo-3'-deoxyuridine (BrdU) incorporation with 
the Cell Proliferation ELISA BrdU (Roche, Mannheim, 
Germany). Briefly, cells were cultured in 96-multiwell 
plates with black, flat bottom (BD Biosciences) in a 
volume of 100 µl/well and transfected. After 72 hours, 
the cells were treated with BrdU labeling solution and 
incubated at 37 °C for additional 2 hours. The cells were 
then fixed for 30 minutes at room temperature with 200 
µl/well of FixDenat buffer, and incubated with 100 µl/
well of anti-BrdU-POD (peroxidase) for 90 minutes at 
room temperature. After three washes, substrate solution 
was added, plates were kept on a shaker for 3 minutes at 
room temperature, and light emission was read by using a 
microplate luminometer with photomultiplier technology 
(DL Ready Berthold Technologies Centro, Beckman, Brea, 
CA, USA). Experiments were performed in triplicate.
Statistical analysis
Statistical analyses were performed using a paired, 
two-tailed Student’s t test (GraphPad Prism 3.0, GraphPad 
Software, San Diego, CA, USA), and differences were 
considered to be statistically significant at a value of p 
≤0.05.
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